340B Insider Summary Report

September 6, 2022

Compliance and manufacturer restrictions top concerns for providers

Meeting program-compliance requirements and pushing back on escalating manufacturer restrictions are the top concerns of pharmacy leaders, as uncovered during the August 2022 R1 340B Insider interactive webinar.

A full 72% of respondents cited one or the other as their primary program concern, with revenue loss largely resulting from discount restrictions ranked third.


Download the full summary report for more information on:

  • Additional industry insights.
  • Regulatory updates from the experts.
  • Advice on how to offset savings loss.
  • What to know about compliance and Health Resources and Services Administration audits.
  • FAQs answered by an expert panel.

Subscribe to our email list to get the latest in your inbox